Rahul D Tendulkar1, Shree Agrawal1, Tianming Gao1, Jason A Efstathiou1, Thomas M Pisansky1, Jeff M Michalski1, Bridget F Koontz1, Daniel A Hamstra1, Felix Y Feng1, Stanley L Liauw1, Matthew C Abramowitz1, Alan Pollack1, Mitchell S Anscher1, Drew Moghanaki1, Robert B Den1, Kevin L Stephans1, Anthony L Zietman1, W Robert Lee1, Michael W Kattan1, Andrew J Stephenson1. 1. Rahul D. Tendulkar, Tianming Gao, Kevin L. Stephans, Michael W. Kattan, and Andrew J. Stephenson, Cleveland Clinic; Shree Agrawal, Case Western Reserve University School of Medicine, Cleveland, OH; Jason A. Efstathiou and Anthony L. Zietman, Massachusetts General Hospital, Boston, MA; Thomas M. Pisansky, Mayo Clinic, Rochester, MN; Jeff M. Michalski, Washington University, St Louis, MO; Bridget F. Koontz and W. Robert Lee, Duke University, Durham, NC; Daniel A. Hamstra, The Texas Center for Proton Therapy, Irving, TX; Felix Y. Feng, University of Michigan, Ann Arbor, MI; Stanley L. Liauw, University of Chicago, Chicago IL; Matthew C. Abramowitz and Alan Pollack, University of Miami, Miami, FL; Mitchell S. Anscher and Drew Moghanaki, Virginia Commonwealth University; Drew Moghanaki, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA; and Robert B. Den, Thomas Jefferson University, Philadelphia, PA.
Abstract
PURPOSE: We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. METHODS: Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. RESULTS: Overall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months). The median pre-SRT PSA was 0.5 ng/mL (interquartile range, 0.3 to 1.1). The 5-yr FFBF rate was 56% overall, 71% for those with a pre-SRT PSA level of 0.01 to 0.2 ng/mL (n = 441), 63% for those with a PSA of 0.21 to 0.50 ng/mL (n = 822), 54% for those with a PSA of 0.51 to 1.0 ng/mL (n = 533), 43% for those with a PSA of 1.01 to 2.0 ng/mL (n = 341), and 37% for those with a PSA > 2.0 ng/mL (n = 323); P < .001. On multivariable analysis, pre-SRT PSA, GS, EPE, SVI, surgical margins, ADT use, and SRT dose were associated with FFBF. Pre-SRT PSA, GS, SVI, surgical margins, and ADT use were associated with DM, whereas EPE and SRT dose were not. The nomogram concordance indices were 0.68 (FFBF) and 0.74 (DM). CONCLUSION: Early SRT at low PSA levels after RP is associated with improved FFBF and DM rates. Contemporary nomograms can estimate individual patient outcomes after SRT in the modern era.
PURPOSE: We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. METHODS: Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. RESULTS: Overall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months). The median pre-SRT PSA was 0.5 ng/mL (interquartile range, 0.3 to 1.1). The 5-yr FFBF rate was 56% overall, 71% for those with a pre-SRT PSA level of 0.01 to 0.2 ng/mL (n = 441), 63% for those with a PSA of 0.21 to 0.50 ng/mL (n = 822), 54% for those with a PSA of 0.51 to 1.0 ng/mL (n = 533), 43% for those with a PSA of 1.01 to 2.0 ng/mL (n = 341), and 37% for those with a PSA > 2.0 ng/mL (n = 323); P < .001. On multivariable analysis, pre-SRT PSA, GS, EPE, SVI, surgical margins, ADT use, and SRT dose were associated with FFBF. Pre-SRT PSA, GS, SVI, surgical margins, and ADT use were associated with DM, whereas EPE and SRT dose were not. The nomogram concordance indices were 0.68 (FFBF) and 0.74 (DM). CONCLUSION: Early SRT at low PSA levels after RP is associated with improved FFBF and DM rates. Contemporary nomograms can estimate individual patient outcomes after SRT in the modern era.
Authors: Alan Dal Pra; Cedric Panje; Thomas Zilli; Winfried Arnold; Kathrin Brouwer; Helena Garcia; Markus Glatzer; Silvia Gomez; Fernanda Herrera; Khanfir Kaouthar; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Rudolf Zwahlen; Daniel Engeler; Paul Martin Putora Journal: Strahlenther Onkol Date: 2017-06-27 Impact factor: 3.621
Authors: Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli Journal: Radiol Med Date: 2018-08-16 Impact factor: 3.469
Authors: Jessica L Robinson; Katherine S Tzou; Alexander S Parker; Michael G Heckman; Kevin J Wu; Tracy W Hilton; Thomas M Pisansky; Steven E Schild; Jennifer L Peterson; Laura A Vallow; Steven J Buskirk Journal: Br J Radiol Date: 2017-06-16 Impact factor: 3.039
Authors: Benedikt Kranzbühler; Hannes Nagel; Anton S Becker; Julian Müller; Martin Huellner; Paul Stolzmann; Urs Muehlematter; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-14 Impact factor: 9.236
Authors: Amar U Kishan; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Kiri A Sandler; Richard G Stock; Gregory S Merrick; D Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Andrew J Stephenson; Eric A Klein; Daniel Y Song; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Johnathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King Journal: JAMA Date: 2018-03-06 Impact factor: 56.272
Authors: Julian Müller; Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Sarah Kedzia; Daniel Eberli; Matthias Guckenberger; Stephanie G C Kroeze; Tullio Sulser; Daniel M Schmid; Aurelius Omlin; Alexander Müller; Thomas Zilli; Hubert John; Helmut Kranzbuehler; Philipp A Kaufmann; Gustav K von Schulthess; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-28 Impact factor: 9.236
Authors: William L Hwang; Rahul D Tendulkar; Andrzej Niemierko; Shree Agrawal; Kevin L Stephans; Daniel E Spratt; Jason W Hearn; Bridget F Koontz; W Robert Lee; Jeff M Michalski; Thomas M Pisansky; Stanley L Liauw; Matthew C Abramowitz; Alan Pollack; Drew Moghanaki; Mitchell S Anscher; Robert B Den; Anthony L Zietman; Andrew J Stephenson; Jason A Efstathiou Journal: JAMA Oncol Date: 2018-05-10 Impact factor: 31.777
Authors: Louise Emmett; Ur Metser; Glenn Bauman; Rodney J Hicks; Andrew Weickhardt; Ian D Davis; Shonit Punwani; Greg Pond; Sue Chua; Bao Ho; Edward Johnston; Frederic Pouliot; Andrew M Scott Journal: J Nucl Med Date: 2018-11-15 Impact factor: 10.057